Cambridge Healthtech Institute's Fifth Annual

Enhancing Antibody Binding and Specificity

( 抗体结合与专一性强化 )

Scientific Strategies for Engineering Biotherapeutic Binding and Specificity for Next-Generation Antibody Therapeutics

2018年1月9日 - 10日


As the industry expands its repertoire of antibody drug products into new therapeutic areas, product formats and protein constructs, the control of antibody/antigen targeting, binding and specificity will take on a new level of importance for researchers in this field. The second meeting in the Peptalk Protein Engineering & Development pipeline, Cambridge Healthtech Institute's Fifth Annual Enhancing Antibody Binding and Specificity, presents innovative approaches to the modulation of binding activity for traditional antibodies, new product formats and difficult targets such as transmembrane proteins.

Preliminary Agenda

Topic to be Announced

Philip M. Kim, Ph.D., Associate Professor, Computational and Integrative Biology, University of Toronto, Canada


Affinity Tuned CAR-T Cells

Mauro Castellarin, Ph.D., Postdoctoral Researcher, June Laboratory, Pathology and Laboratory Medicine, University of Pennsylvania

Engineering a Therapeutic Antibody for Long-Acting Delivery to the Eye

Devin Tesar, Ph.D., Scientist, Drug Delivery, Genentech

Cytosol-Penetrating Antibody Technology for Targeting Intracellular Proteins

Yong-Sung Kim, Ph.D., Professor, Molecular Science and Technology, Ajou University, Korea


Robust Determination of Antibody Affinity to Cells Using Flow Cytometry

Timothy Fenn, Ph.D., Principal Scientist, Boehringer Ingelheim

Modeling Protein-Protein Complexes: The Good, the Bad and the Ugly

Enrico Purisima, Ph.D., Team Leader, Molecular Modeling, National Research Council Canada


Conditional Fc Receptor Interactions - What Effector Cells Are Interested In

Tilman Schlothauer, Ph.D., Principal Scientist, Biochemical and Analytical Research, Large Molecule Research, Roche Innovation Center Munich, Germany

Comparison of Biosensor Platforms in the Evaluation of High Affinity Antibody-Antigen Binding Kinetics

Rachel Kroe-Barrett, Ph.D., Director, Biophysics, Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals

Subtype Cross-Species Reactivity

Mehabaw G. Derebe, Ph.D., Scientist, Biologics Engineering, Janssen BioTherapeutics


Engineered Clearing Agents for the Selective Depletion of Antigen-Specific Antibodies

E. Sally Ward, Ph.D., Professor, Molecular and Cellular Medicine, Texas A&M Health Science Center

Altering Antibody Specificities for Better Clearance

Madhu Natarajan, Ph.D., Preclinical Therapeutic Area Head, Ophthalmology & Complement Biology, Shire

Highly Efficient Recovery of GPCR-Specific Antibodies Coupling Yeast Library Selection and Next-Generation Sequencing

Robert Pejchal, Ph.D., Scientist, Antibody Engineering, Adimab LLC

ProTIA - Bispecific T Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., President and CEO, Amunix

Pre-Targeting Strategies for Improved Specificity of Antibody Therapeutics

Jonathan Wall, Ph.D., Professor, Medicine; Director, Preclinical and Diagnostic Molecular Imaging Laboratory, University of Tennessee Medical Center

* 活动内容有可能不事先告知作更动及调整。